MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients
Status:
Not yet recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
The proposed study in patients with previously untreated locally advanced head and neck
squamous cell carcinoma (HNSCC) is designed to evaluate the efficacy and safety of three
different doses of MIT-001 compared to the placebo in prevention of oral mucositis (OM) in
patients with HNSCC who are undergoing concurrent chemoradiotherapy (CCRT).